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Abstract 
Background: Upcoming KDIGO guidelines for the evaluation of living kidney donors are expected to 
move towards a personal risk based evaluation of potential donors. We present the age and sex 
specific lifetime risk of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 10 
European countries. 
Methods: We defined lifetime risk of RRT as the cumulative incidence of RRT up to age 90. We 
obtained RRT incidence rates per million population by five year age groups and sex using data from 
the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry, 
and used these to estimate the cumulative incidence of RRT, adjusting for competing mortality risk.  
Results: Lifetime risk of RRT varied from 0.44% to 2.05% at age 20  and from 0.17% to 1.59% at age 
70 across countries, and was twice as high in men as in women. Lifetime RRT risk decreased with age, 
ranging from an average of 0.77% to 0.44% in 20 to 70 year old women, and from 1.45% to 0.96% in 
20 to 70 year old men. The lifetime risk of RRT increased slightly over the past decade; more so in 
men than in women. However, it appears to have stabilized or even decreased slightly in more recent 
years.    
Conclusions: The lifetime risk of RRT decreased with age, was lower in women as compared to men 
of equal age and varied considerably throughout Europe. Given the substantial differences in lifetime 
risk of RRT between the USA and Europe, country specific estimates should be used in the evaluation 
and communication of the risk of RRT for potential living kidney donors.   
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Short summary 
Recently a risk prediction model for potential kidney donors has been created for persons living in 
the USA. However, these estimates may not be generalizable to European populations. We provide 
reference values for lifetime risk of renal replacement therapy for ESRD in European countries 
participating in the ERA-EDTA Registry, a registry of all patients receiving renal replacement therapy 
(dialysis or a kidney transplant) in several countries across Europe. We showed that the risk of RRT 
was considerably lower in European countries compared to the USA. Moreover, we noted substantial 
variation in the lifetime risk of renal replacement therapy across Europe. Therefore, country specific 
estimates of lifetime renal replacement therapy risk should be used when evaluating a potential 
kidney donor. 
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Introduction 
A living donor kidney transplant is the preferred treatment option for a patient with end-stage renal 
disease (ESRD). For the living donor, donating a kidney offers the potential opportunity to extend 
another life. However, those donating a kidney may themselves be at an increased risk of ESRD.[1] 
Therefore, we must ensure that those wishing to donate a kidney are adequately informed of their 
long-term risk of developing ESRD. Moreover, the new Kidney Disease Improving Global Outcomes 
(KDIGO) guidelines for the evaluation and follow-up care of living kidney donors are expected to 
move towards personalized, risk based screening of potential donors. One of the likely 
recommendations will be that an individual may be accepted as a living kidney donor if their lifetime 
ESRD risk is below a certain threshold. In order to obtain a personalized lifetime ESRD risk estimate 
for a potential donor, one needs both a population reference for lifetime ESRD risk and information 
on his or her individual risk factors for ESRD. Recently the Chronic Kidney Disease (CKD) Prognosis 
Consortium published such a risk prediction model for the lifetime risk of ESRD in potential kidney 
donors.[2] This model was based on populations from Canada, the USA and Israel,[2, 3] and may not 
be generalizable to European populations. For example, the incidence of renal replacement therapy 
(RRT), defined as haemodialysis, peritoneal dialysis and kidney transplantation, in the United States is 
almost two times higher than that of Belgium and Greece, both countries with the highest incidence 
of RRT in Europe.[4, 5] Therefore, a population reference for lifetime risk of ESRD specific for 
European countries is required to feed any future prediction models in the European setting. To date, 
country specific estimates of lifetime RRT risk for Europe are lacking. In this study we present the age 
and sex specific lifetime risk of RRT in 10 European countries. 
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Subjects and Methods 
Data sources and design 
We performed a population based study using data obtained from the European Renal Association - 
European Dialysis and Transplantation Association (ERA-EDTA) Registry and publically available data 
from EuroStat. The primary outcome of the study was RRT for ESRD, defined as commencing chronic 
RRT, defined as haemodialysis, haemodiafiltration, peritoneal dialysis or pre-emptive kidney 
transplantation.[4] Death was considered a competing event.  
The ERA-EDTA Registry 
Data from twelve national or regional renal registries (Austria, Dutch-speaking Belgium, French-
speaking Belgium, Denmark, Finland, France, Greece, the Netherlands, Norway, Sweden, the United 
Kingdom [UK]: England/Wales/Northern Ireland and the UK: Scotland), providing individual level data 
on patients receiving chronic RRT for ESRD to the ERA-EDTA Registry between 2002-2011 were 
included in the study. All registries provided data for the entire time period, with the exception of 
France (from 2006 onward). 
Data relevant to the present study were a unique patient study number, country of registry, date of 
birth, sex and date of initiation of RRT. Patients commencing RRT for ESRD were included in the 
study. The details of the methods used by the ERA-EDTA Registry for data collection and data 
processing of the database can be found in the ERA-EDTA Registry annual report.[4] Informed 
consent was not separately obtained for the present study, as data collection was part of the routine 
work of the participating registries. MP used individual level data to prepare aggregated data files 
(included in the online supplement). JvdB performed the analyses on the aggregated data and had no 
access to individual level data, ensuring privacy. 
Statistical methods 
Incidence of renal replacement therapy by sex and age 
We defined lifetime risk of RRT as the cumulative incidence of commencing RRT before age 90. We 
defined lifetime risk of RRT in the year 2011 as the primary outcome. The exposures of interest were 
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index age and sex. We defined the index age as the age that a person has reached without requiring 
RRT for ESRD. In addition, we assumed that the population within each country was at a steady state 
over the course of a year. This assumption allowed us to estimate the annual incidence rate of RRT 
from the incidence of RRT per million population (pmp) by five year age groups and sex for each 
country included in the study. [6] The incidence of RRT pmp was defined as the number of patients 
starting RRT annually divided by the mid-year general population within a five year age group and by 
sex. To minimize the effects of late reporting by the renal registries the analyses of the incidence of 
RRT between 2002 and 2011 were based on the ERA-EDTA Registry 2012 database.[4] The general 
population data and sources needed for the calculation of the incidence of RRT pmp are available 
from the corresponding author upon request.   
Persons who are at increased risk of RRT are also at an increased risk of mortality.[7] Therefore, 
within survival analyses, death is a competing event, and should be accounted for when estimating 
the cumulative incidence of RRT.[8] Similar to the method in which we estimated the annual RRT 
incidence pmp, we estimated annual mortality per million of age related population (pmarp). First, 
we obtained the total population size and the number of deaths by five year age and sex strata for 
each of the participating countries from EuroStat (accessed 12th December 2014). Next, we divided 
the number of deaths by the total number of persons within each age and sex group. We 
subsequently used the incidence of RRT and mortality pmarp to estimate the number of RRT cases 
and deaths by five year age group and sex in the populations from which RRT incidence was 
obtained.  
Lifetime risk of renal replacement therapy 
In order to estimate the lifetime risk of RRT while taking competing mortality risk into account, we 
first used the number of RRT cases and deaths to estimate annual incidence rate for both RRT and 
death using Stata’s stcompet function.[9, 10] We extrapolated the annual incidence rate according to 
the method described by Beiser et al.[11] Box 1 shows a brief description and example of this 
approach. We took ages 20 to 85 in five year intervals as index ages. In addition, we calculated the 
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ratio of the lifetime risk of RRT in women compared to men to investigate possible trends in sex 
specific uptake of RRT with age. Finally, we pooled the lifetime risk of RRT across Europe by 
calculating the inverse variance weighted mean of the country specific lifetime risk of RRT by index 
age. Additionally, in order to assess if possible differences in lifetime risk of RRT were due to 
differences in life expectancy, we checked for possible correlations between lifetime risk of RRT and 
life expectancy by 10 year increments of index age and by sex. We did not perform statistical 
significance tests for between country differences in lifetime risk of RRT. As the differences were 
substantial and the confidence intervals narrow, a difference greater than 0.05 percentage point 
would have been statistically significant.  
Trends in lifetime risk of renal replacement therapy from 2002 to 2011 
In order to study possible time trends in lifetime risk of RRT, we repeated the analyses for the years 
2002 to 2010. In this analysis we only included the countries that provided data for the entire period 
from 2002 to 2011. We evaluated time trends from 2002 to 2011 using ordinary least squares 
regression with segments (R package segmented). First, we fitted a linear regression for women and 
men and index ages 20, 30, 40, 50, 60 and 70 years separately. Next we added a single knot and 
compared the segmented regression to the linear regression using ANOVA. If the segmented 
regression showed a better fit compared to the linear model another knot was added and compared 
to the regression with a single knot. We repeated this process until the model did not improve with 
the addition of further knots.  
The analysis scripts that we used (Stata 11.2, StatCorp, TX, USA; and R, www.r-project.org, version 
3.1.1), are available from the corresponding author upon request. 
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Results 
Lifetime risk of renal replacement therapy by sex and age 
In order to estimate the lifetime risk of RRT, we first estimated the annual incidence rate of RRT. 
Figure 1 shows pooled estimates of cumulative incidence of RRT by index age. The cumulative 
incidence of RRT increases more steeply at higher index ages compared to a low index age. However, 
the lifetime risk of RRT is higher at the lowest index ages, as illustrated in Figure 2. Men had a higher 
lifetime RRT risk than women across all index age groups and countries. For example, at index age 20, 
lifetime RRT risk varied between 0.44% (Finland) and 1.20% (Greece) for women, and between 0.88% 
(Finland) and 2.05% for men (Belgium). At age 40, lifetime RRT risk varied between 0.41% (Finland) 
and 1.17% (Greece) for women and between 0.83% (Finland) and 1.99% for men (Belgium). At age 
60, lifetime RRT risk was lower still, ranging between 0.31% (Finland) and 1.05% (Greece) for women 
and 0.69% (Finland) and 1.83% (Belgium) for men. See the supplements for more detailed tables of 
lifetime risk of RRT.  
 Overall, the lifetime risk of RRT was approximately twice as high in men compared to women at 
index ages less than 65 years. However, after the age of 70, the ratio increased. At age 80 the 
average lifetime risk of RRT was 2.5 times as high in men and at age 85 it was three times as high in 
men as in women. This trend was observed in all countries except Greece, where the ratio remained 
stable across all age groups. 
Lifetime risk of renal replacement therapy by country 
The pooled lifetime RRT risk in Europe was 0.73%, 0.68% and 0.58% in 40, 50 and 60 year-old 
women, respectively. By comparison, in men the pooled lifetime RRT risk was 1.40%, 1.32% and 
1.18% at index ages 40, 50 and 60, respectively. However, we noted variation across European 
countries. The lifetime RRT risks were lowest in the Scandinavian countries and the United Kingdom, 
and highest in Belgium and Greece.  No statistically significant correlations for a possible association 
between lifetime risk of RRT and life expectancy were observed (data not shown). Tables with 
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country specific lifetime RRT risk estimates by five year increments of index age can be found in the 
supplementary appendix online.  
Trends in lifetime renal replacement therapy risk from 2002 to 2011 
Figure 3 shows pooled lifetime RRT risks in Europe between 2002 and 2011 by sex and ten year 
intervals of index age. Table 1 shows the trends in the lifetime risk of RRT between 2002- 2011 by sex 
and index age. In general, from 2002 onward lifetime RRT risk increased in both men and women. 
The overall increase of lifetime RRT risk was more pronounced in men, who showed a marked 
increase in lifetime risk of RRT until 2008 and a slight decrease in lifetime risk of RRT thereafter. 
Likewise, lifetime RRT risk stabilized in women after 2009. Overall, changes in lifetime risk of RRT 
over time were modest.  
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Discussion 
This study describes the age and sex specific lifetime risk of RRT in 10 European countries and the 
average lifetime RRT risk across Europe. Even though the annual incidence rate of RRT is higher in 
older people compared to young people, the lifetime risk of RRT is lower in older people. In addition, 
lifetime risk of RRT is lower in women compared to men of the same age. We noted a substantial 
difference in lifetime RRT risk between countries. For instance, Belgium and Greece had a relatively 
high lifetime RRT risk compared to the rest of Europe, whereas the lifetime RRT risk was relatively 
low in Denmark, Finland, and Norway. Finally, the lifetime risk of RRT increased slightly over the past 
decade; more so in men than in women. However, it appears to have stabilized or even decreased 
slightly in recent years. 
Relation to other studies 
Estimates of lifetime risk of RRT have been provided previously for both the USA and Canada.[3, 12] 
At all ages, the lifetime risk of RRT in both the USA and Canada was two to three times as high in 
both men and women compared to our study. A possible explanation for the difference between the 
Canadian study and our study may be that persons in the Canadian study were included only if they 
had a serum creatinine level determined during an outpatient visit. Consequently, persons with 
kidney disease or co-morbidities were more likely to be included in their study sample. By using 
general population data we have attempted to remove this selection bias. The study from the USA, 
however, was a simulation study based on population data collected from the United States Renal 
Data System, the American registry for RRT,[12] and therefore selection bias is unlikely to explain the 
difference. Another possible explanation may be differences in the prevalence of risk factors for 
more rapid progression of CKD to ESRD. Even though the prevalence of raised blood pressure is lower 
in the USA and Canada compared to Europe,[13] prevalence of underlying risk factors for vascular 
and renal damage, such as diabetes and obesity, is higher.[14, 15] In addition, despite the majority of 
white Americans and Canadians being from European descent, genetic differences cannot be 
excluded. Finally, macro-economic factors and health system wide factors, such as the percentage of 
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the gross domestic product (GDP) per capita spent on healthcare and the proportion of dialysis 
centres providing RRT services for-profit may influence RRT incidence and therefore result in 
differences in lifetime risk of RRT between countries.[16] 
Meaning of this study 
We found that even though cumulative incidence of RRT increases with age, the lifetime RRT risk 
decreases with age. A similar trend was noted in other studies,[3, 12] and it is likely due to both 
competing mortality risk and conditional survival. The impact of competing mortality risk has been 
clearly highlighted by O’Hare and colleagues:[17] the elderly are more likely to die from competing 
causes, such as cardiovascular disease rather than develop ESRD. We took this competing mortality 
risk into account in our analyses.[8, 9] Conditional survival results in a higher probability of reaching 
RRT at some point during the remainder of one’s life for younger people as they have more life years 
left to develop RRT.  
At an index age of 65 years or less, lifetime risk of RRT in women compared to men was almost half in 
all countries in the present study. The reason for this difference is unclear. A recent meta-analysis 
showed that, at a given eGFR and albuminuria level, the risk of developing ESRD, defined as RRT, was 
similar for men and women with chronic kidney disease.[18] Moreover, the risk for all-cause 
mortality was higher in men throughout the eGFR range in general population and high risk cohorts. 
Therefore, the difference in RRT risk between men and women is unlikely to be explained by a 
competing mortality risk. In 2010, the estimated prevalence of hypertension (29.1% versus 21.4%) , 
diabetes (8.2% versus 7.2%), smoking (39.0% versus 19.3%) and high serum cholesterol (54.1% versus 
52.7%) was higher in men than in women across Europe.[13] Differences in these risk factors 
between men and women may account for a substantial part of the difference in lifetime RRT risk. In 
addition, the decline in lifetime risk of RRT was more pronounced in women compared to men across 
Europe, with the exception of Greece, where this trend was not observed. It is unclear why the 
uptake on RRT at higher ages was lower for women compared to men.   
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We noted quite some variation in lifetime risk of RRT between European countries. Similar to the 
differences between Europe and the USA, macro-economic factors such as the GDP per capita and 
percentage of GDP spent on healthcare may contribute in differences in RRT incidence between 
countries within Europe.[16] In addition, differences in prevalence of risk factors such as diabetes 
may contribute to differences in lifetime RRT risk.[19, 20] Furthermore, some of the difference may 
be due to differences in medical practice.[19] For example, in a survey sent out to nephrologists in 11 
European countries, 20% of the nephrologists from high RRT incidence countries reported that, even 
when expected gains in survival and quality of life were low, they always offer the option for RRT 
care compared to 8% of the nephrologists from low RRT incidence countries.[21] Finally, differences 
in life expectancy between countries could result in differences in RRT incidence, and thus lifetime 
risk of RRT. However, we did not observe an association between life expectancy and lifetime risk of 
RRT. 
By estimating the average lifetime risk of RRT in the general population, we provide conservative 
estimates of the lifetime risk of ESRD. These estimates may be useful in the communication of the 
risk of ESRD to the general public, policy makers and individual patients. It is easier to understand 
percentage risk compared to other terms such as relative risks, odds ratios or hazard ratios. It should 
be noted, however, that the life time risk estimates that are presented here are country level 
averages. An individual’s risk of ESRD may be far higher than the average depending on the presence 
of risk factors such as low eGFR, the presence of albuminuria, high blood pressure, comorbidities, 
and a family history of kidney disease. Such risk factors need to be taken into account when 
counseling individual patients. 
Our results indicate that the lifetime risk of RRT in the European general population is substantially 
lower that the lifetime risk of RRT previously estimated for the general population in the USA.[12] 
The latter results were recently used as a reference level in a model predicting the lifetime risk of 
RRT in people who were potential kidney donors, but did not donate a kidney.[2] As the lifetime risk 
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in the European general population is substantially lower than in the USA, the reference level in 
potential living kidney donors is also likely to be lower. Consequently, the risk prediction model that 
was developed by the CKD Prognosis Consortium for people in the USA, Canada and Israel needs to 
be recalibrated and validated before implementation in Europe.  
Finally, it is important to note the lifetime risk of RRT changes after kidney donation. The relative risk 
of RRT for ESRD is between 6 and 12 times higher in people who donated a kidney compared to 
equally healthy controls.[1, 22] whether this elevated risk is acceptable depends on the absolute risk 
of RRT for the potential donor after donation. Together with information on a potential donor’s risk 
factors and the relative risk induced by nephrectomy, country specific reference values for lifetime 
risk of RRT are needed to obtain this absolute risk of RRT after kidney donation. Future studies 
should therefore focus on obtaining more country specific reference risk estimates for lifetime RRT 
before donation; only thereafter, the model by the CKD Prognosis Consortium can be validated in 
different national populations throughout Europe. 
Strengths and weaknesses of the study 
The first strong point of our study was the use of complete population survey data to obtain 
mortality and RRT incidence rates. Instead of taking a sample we were able to include the entire 
general population of each country in our analyses. In addition, the combined RRT registries provided 
full coverage of the population.[4] As a result, selection bias due to either sampling error or 
underreporting is highly unlikely. Second, in older persons the risk of mortality surpasses the risk of 
ESRD and subsequent RRT.[17] We took this competing mortality risk into account in our analyses. 
The present study does have some limitations. First of all, the ERA-EDTA Registry does not include 
information on race. Therefore, we were unable to provide race stratified lifetime risk estimates. 
Second, lifetime RRT risk may underestimate lifetime ESRD risk. We used RRT as a proxy for ESRD, yet 
the two are not synonymous. Some patients, particularly those in older age groups, may opt for 
conservative management of ESRD, and as a result they would not be registered in national or 
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regional renal registries and in turn in the ERA-EDTA Registry. Nephrologists have recently estimated 
the proportion of new ESRD patients treated with conservative management at 10% (inter quartile 
range 5% to 20%).[21] Moreover, we extrapolated incidence estimates obtained from the general 
population to estimate annual incidence rate of RRT in persons without RRT. However, the general 
population includes the prevalent RRT population, i .e. those already receiving RRT. As RRT is 
relatively rare in the general population (i.e. less than 1 in 1000) the influence of this misclassification 
bias on the estimate of RRT incidence will be negligible. In conclusion, the results of our study are 
likely to somewhat underestimate the life time risk of ESRD especially in older age groups and 
therefore our results should be seen as conservative estimates for ‘average’ individuals. Finally, our 
estimates are based on historical data and for this reason they may not fully apply to future 
generations. However, we did not observe strong trends in lifetime RRT risk over the course of the 
past decade. Therefore, we feel that differences in birth cohorts will not substantially affect our 
estimates.  
Conclusion 
The present study describes the lifetime risk of RRT across Europe by sex and age group. This risk was 
lower in higher age groups, and it was lower in women compared to men of the same age. Given the 
substantial differences in lifetime risk of RRT between the USA and Europe, and between countries 
within Europe, country specific estimates of lifetime risk of RRT should be used when communicating 
risks and in the evaluation of potential living kidney donors. 
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Tables 
Box 1.The estimation of lifetime RRT risk from annual RRT incidence per million population. 
Lifetime risk of Renal Replacement Therapy (RRT) is the cumulative incidence of requiring RRT 
during the remainder of an individual’s life from a certain index age at which that person was free 
from RRT.[3] Usually, cumulative incidence is calculated from a cohort of persons who are disease 
free (i.e. did not require RRT) at the cohort’s inception, simply by dividing the number of people who 
have experienced an event during follow-up by the total number of persons in the cohort at its start. 
However, in special circumstances, namely when follow-up time is short and when an event is rare, 
cumulative incidence can be estimated from incidence rates.[6] Whereas cumulative incidence can 
only be obtained from a cohort, incidence rates per million population can be estimated from a 
dynamic population, such as all inhabitants of a country over the period of a year. RRT is a rare 
event in the general population and a single year is sufficiently short to assume that the population 
is in a steady state. Thus, the conditions that enable us to use annual RRT incidence rate per million 
population to estimate the cumulative RRT incidence are met. 
Beiser et al. formulated an approach to extrapolate cumulative incidence to lifetime risk that takes 
into account survival up to a certain age – called the index age.[11] First, one-year RRT incidence 
rates by age strata are calculated. Next, these age specific incidence rates are used to calculate 
cumulative incidence for persons who have survived to a certain age, as shown in the following 
example: 
Assume that the annual incidence rate of an event for persons aged 40 to 44 is 0.02 per 100 person 
years, whereas it is 0.05 per 100 person years for those aged 45 to 49. If we would have 1000 
persons aged 43, how many would suffer the event by age 47?  
Knowing the incidence rate, we can calculate the cumulative incidence as follows: 
Age Events Surviving Cumulative Incidence 
43  44 0.02 ∙ 1000 = 20 980 2.0% 
44  45 0.02 ∙ 980 = 19.2 ≈ 19 961 3.9% 
45  46 0.05 ∙ 961 = 48.1 ≈ 48 913 8.7% 
46  47 0.05 ∙ 913 = 45.7 ≈ 46 867 13.3% 
The above calculation is a simplification and not the actual calculation used in the present paper, as 
competing risk of death is not taken into account here. However, the approach remains 
conceptually similar when competing risks are accounted for. An annotated analysis script with the 
actual calculations is available upon request from the corresponding author. 
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Table 1. Trends in lifetime RRT risk between 2002 and 2011 by sex and index age.  
Index age Years Change in lifetime RRT risk 
per year (%) 
95% Confidence interval 
Women 
     20 2002-2009 +0.007 0.000 - +0.014 
 
2010-2011 -0.026 -0.054 - +0.001 
30 2002-2009 +0.007 +0.002 - +0.012 
 
2010-2011 -0.060 -0.107 - -0.013 
40 2002-2009 +0.009 +0.003 - +0.014 
 
2010-2011 -0.023 -0.044 - -0.001 
50 2002-2009 +0.008 +0.003 - +0.013 
 
2010-2011 -0.059 -0.105 - -0.013 
60 2002-2009 +0.009 +0.003 - +0.014 
 
2010-2011 -0.023 -0.044 - -0.001 
70 2002-2009 +0.008 +0.003 - +0.013 
 
2010-2011 -0.055 -0.101 - -0.009 
Men 
     20 2002-2008 +0.034 +0.025 - +0.043 
 
2009-2011 -0.020 -0.037 - -0.002 
30 2002-2008 +0.041 +0.030 - +0.051 
 
2009-2011 -0.020 -0.039 - -0.001 
40 2002-2008 +0.038 +0.028 - +0.048 
 
2009-2011 -0.017 -0.035 - +0.001 
50 2002-2008 +0.038 +0.028 - +0.047 
 
2009-2011 -0.017 -0.035 - +0.000 
60 2002-2008 +0.032 +0.022 - +0.042 
 
2009-2011 -0.018 -0.037 - +0.001 
70 2002-2008 +0.032 +0.027 - +0.042 
 
2009-2011 -0.018 -0.036 - -0.000 
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Legends to the figures 
 
Figure 1. Cumulative incidence of renal replacement therapy in Europe by age for women (left panel) 
and men (right panel), respectively.  
 
Figure 2. Lifetime risk of renal replacement therapy in Europe by index age for women (left panel) 
and men (right panel). The thick dotted line represents the pooled lifetime risk of renal replacement 
therapy. The country specific estimates are indicated by the colour coded abbreviations. Bel: 
Belgium, Gre: Greece, Fra: France, Aut: Austria, NL: the Netherlands, Swe: Sweden, UK: The United 
Kingdom, Den: Denmark, Nor: Norway, Fin: Finland. 
 
Figure 3. Trends in lifetime risk of renal replacement therapy in Europe between 2002 and 2011 by 
sex at index ages 20, 30, 40, 50, 60 and 70 (from top to bottom).  
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